Research Article
Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Figure 1
Survival depending on KRAS mutational status in the whole study population (HR 2.32, , 95% CI 1.27–4.26).